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ABSTRACT
After allogeneic stem cell transplantation (allo-SCT) some patients develop persistent anemia in associationwith
an inadequate erythropoietin (Epo) secretion. We determined the frequency and risk factors for this complica-
tion and the response to treatment with erythropoiesis stimulating proteins (ESP). Of 83 evaluable allo-SCT pa-
tients, 63 (76%) developed persistent anemia at a median of 34 (range: 30-244) days after allo-SCT. Forty-one
(49%) patients had anemia considered as primary, and in all of them inadequate serum Epo levels (median 43.3,
range: 2.5-134,mU/mL)were found. A high creatinine level during the firstmonth after allo-SCTwas associated
with primary anemia (relative risk [RR] 2.5, P5 .01). Of the 41 patients, 35 received ESP. Transfusion indepen-
dence and an Hb level higher than 10 g/dL was achieved in 29 of 30 (97%) evaluable patients. Median ferritin
levels at the beginning and at the end of the ESP treatment was 1628 (range: 168-5208) and 805 (range: 14-7443)
ng/mL, respectively (P 5 .04). In conclusion, anemia associated with impaired Epo secretion after allo-SCT is
more frequent than usually recognized and it is associated to early postransplantation renal damage. This com-
plication easily reverts with ESP, which seems to contribute to reduce iron overload.
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Persistent anemia is common after allogeneic stem
cell transplantation (allo-SCT), with some patients
requiring red blood cell transfusions for as long as 1
year [1]. This is of medical concern because repeated
transfusions are associated with iron overload and an
increased risk of infections [2-5]. The etiology of the ane-
mia after allo-SCT ismultifactorial, but inadequate stim-
ulus of erythroid progenitors by erythropoietin (Epo)
seems to play an important role [1]. Thus, although
serum Epo levels are increased within the first month
after transplantation, Epo secretion is impaired after-
ward, resulting in inappropriately low levels for the
degree of anemia for up to 6 months or 1 year [1,6-10].
Although impaired Epo secretion from allo-SCT was880described 15 years ago, the incidence of anemia because
of this cause has not been fully investigated.
Epo is synthesized by peritubular interstitial cells
of the kidney in response to hypoxia [11-13]. The
number of Epo-producing cells in the kidney has
been shown to increase exponentially in response to
anemia [14]. Cyclosporine A (CsA) is associated with
tubular nephrotoxicity, and significantly impairs the
ability of anemic patients to mount an adequate Epo
response to anemia [1,15]. However, not all individuals
receiving CsA develop anemia. Risk factors that
contribute to anemia associated to an impaired Epo
secretion after allo-SCT have not been identified.
Several groups have used erythropoiesis stimulat-
ing proteins (ESP) to accelerate erythropoietic
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clinical usefulness is controversial, because in most
clinical trials Hb levels were modestly improved by
ESP and transfusion requirements were only margin-
ally decreased [17,18]. These disappointing results
might be explained by the fact that ESP was given
from days 1 through 30 to day 55 or until erythroid
engraftment, a period with a marked endogenous
Epo release [1], and because patients received ESP
regardless of whether they were anemic or not. A
more rational use of ESP after allo-SCT has been
only anecdotally reported [19].
Against this background, we investigated the effec-
tiveness of ESP administration in patients having
received an allotransplantation, with persistent
primary anemia beyond day 130 and with demon-
strated inadequate Epo secretion. We also looked for
the incidence and risk factors associated with this com-
plication and tried to quantify the benefits of the indi-
vidualized utilization of ESP after allo-SCT.
PATIENTS AND METHODS
Patients
BetweenMay 2002 and February 2005, 87 patients
with hematologic diseases were submitted to allo-SCT
in our institution. All of them received CsA as GVHD
prophylaxis. Of them, 4 patients had a postransplanta-
tion survival shorter than 30 days and were excluded
from this study. Detailed clinical characteristics of
the 83 evaluable patients are listed in Table 1. The
Hospital Clinic Ethical Committee approved the study
and all patients signed a written informed consent.
Definitions
Patients with acute leukemia in first remission,
chronic myelogenous leukemia (CML) in the chronic
phase, and other hematologic malignancies in remis-
sion were classified as being in early stage. Patients
with acute leukemia in the second or subsequent
remission, multiple myeloma (MM), or other hemato-
logic diseases in relapse were considered as in advanced
stage [22]. Persistent anemia was considered when
patients presented with hemoglobin concentration
(Hb) lower than 10 g/dL beyond 30 days of transplan-
tation, with or without RBC transfusion need. Persis-
tent anemia was considered as secondary when an
evident etiology (hemorrhage, graft failure, hemolysis,
relapse of the hematologic disease, thrombotic micro-
angiopathy, or severe infection) was present. Anemia
was considered as primary when no evident cause for
it was found. Inadequate Epo secretion was defined
by either graphic or quantitative method (Epo\100
mU/mL in patients with Hb\10 g/dL) [23]. Renal
function of each patient was evaluated by taking the
maximum creatinine level during the first month of
the transplantation and by the glomerular filtrationcalculated by Cockcroft-Gault formule (GF 5 [(140
2 age)  kg body weight]/(72  creatinine [mg/dL])
(0.85 in females). Iron overload was defined as a fer-
ritin level .1000 ng/mL [24,25].
Laboratory Analyses
Complete blood counts were determined in
ADVIA 120 and 2120 autoanalyzers (Bayer Diagnos-
tics, Barcelona, Spain). Serum Epo level was measured
by commercially available ELISA (R&D Systems,
Minneapolis, MN), with normal values ranging from
4 to 20 mU/mL. Ferritin level was measured by the
immunoassay method in an ADVIA Centaur autoana-
lyzer (Bayer Diagnostics).
ESPAgents
The first 11 consecutive patients received epoietin
a (Eprex, Janssen-Cilag, or Epopen, Pensa) at a stan-
darddosageof10,000 IU3 timesweekly, subcutaneously,
Table 1. Patient’s Description
Patient’s Description n 5 83
Age (years), median (range) 41 (19-64)
Sex (M/F), n (%) 47/36 (56.6/43.4)
ABO compatibility, n (%)
Compatible 42 (50.6)
Minor incompatibility 23 (27.7)
Major incompatibility 15 (18.1)
Combined major/minor incompatibility 3 (3.6)
Creatinine pre allo-SCT (mg/dL),
median (range)
1.0 (1-2)
Stage of disease, n (%)
Early 35 (42.2)
Advanced 48 (57.8)
Conditioning regimen, n (%)
Myeloablative 56 (67.5)
TBI 49 (59)
No TBI 7 (8.5)
RIC 27 (32.5)
TBI 3 (3.6)
No TBI 24 (28.9)
Donor, n (%)
HLA-identical sibling 57 (68.7)
Unrelated 26 (31.3)
Matched 19 (22.9)
Mismatched 7 (8.4)
Stem cells source, n (%)
PB 69 (83.1)
BM 13 (15.7)
PB 1 BM 1 (1.2)
CD341 cell dose (106/kg body weight),
median (range)
4.2 (1-16)
AgCMV1 before day 1 90, n (%) 34 (40.9)
Ganciclovir 14 (16.9)
Foscarnet 11 (13.2)
Valganciclovir 1 (1.2)
Ganciclovir 1 Foscarnet 7 (8.4)
No treatment 1 (1.2)
M indicates male; F, female; TBI, total body irradiation; RIC,
reduced-intensity conditioning; PB, peripheral blood; BM,
bone marrow.
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a (Aranesp, Amgen, Thousand Oaks, CA) at a standard
dosage of 150 mg per week, subcutaneous. The only
reason for changing epoietin to darbepoietin was the
more convenient administration of darbepoietin a (once
per week) compared to epoietin a (3 times per week).
The objective of the treatment was to increase the Hb
level over to 11 g/dL, and when raised to a level of $13
g/dL, the ESP treatment was interrupted.
Evaluation of Response to ESP
A major response was defined as an increment .2
g/dL in the Hb level, and by achievement of Hb level
.10 g/dL without RBC transfusion needed, both
within 4 weeks of starting the treatment. A minor
response was considered when only 1 of these 2 criteria
was fulfilled [19,26].
Statistical Method
The study was designed to identify the incidence
and factors associated to primary anemia, to evaluate
the degree of response to ESP, and to determine
whether ESP treatment mobilizes iron overload.
Characteristics considered to be associated with
primary anemia were age, sex, ABO compatibility
between patient and donor, maximum creatinine level
between 1 and 30 days after allo-SCT, stage of disease
(early versus advanced), preparative regimen (myeloa-
blative versus reduced intensity (RIC), total body irra-
diation (TBI), number of CD341 cells infused, source
of stem cells, type of donor (HLA-identical sibling or
unrelated), presence of acute GVHD (aGVHD) (0-I
versus II-IV), positive CMV antigenemia and its treat-
ment (either ganciclovir or foscarnet were used
depending on the presence renal disfunction or cyto-
penia, respectively), days to reach absolute neutrophil
count (ANC).0.5 109/L, and days to achieve plate-
let count .50  109/L. Descriptive analyses are
reported as frequencies and percentages, median, and
range. Pearson’s chi-square (c2) test, Fisher’s exact
test, or Student’s test were used to compare 2 groups.
All reported P values are 2 sided, and a significance
level of a 5 0.05 was used. All prognostic variables
in the univariate analysis with a value of P\ .1 were
included for the multivariate analysis to ensure that
each characteristic was individually significant. The
multivariate analysis was performed using the logistic
regression model. Statistical studies were performed
by mean of SPSS 12.0 version statistical software.
RESULTS
Incidence of Primary Anemia and Impaired Epo
Secretion
Sixty-three of the 83 (76%) patients presented with
persistent anemia at a median of 34 (range: 30-244)
days after allo-SCT. In 22 (27%) cases the anemiawas secondary to transplantation-related complica-
tions: hemorrhage (n 5 10, 15.8%), graft failure
(n5 3, 4.8%), relapse (n5 3, 4.8%), thromboticmicro-
angiopathy (n 5 3, 4.8%), severe infection (n 5 2,
3.2%), and hemolysis (n5 1, 1.6%). Secondary anemia
was evident at amedian of 38 (range: 30-158) days post-
ransplantation. In 41 (49%) patients anemia was
considered to be primary, and it was apparent at a me-
dian of 33 (range: 30-244) days, and in all of them serum
Epo level was inadequately low, with a median of 43.3
(range: 2.5-134) mU/mL. One patient, having a serum
Epo level of 134 mU/mL with an Hb of 7.5 g/dL, was
considered to have an inadequate Epo response by the
graphical method [23].
Factors Associated with Primary Anemia
We analyzed the 41 patients that presented
primary anemia, with (n 5 27) or without (n 5 14)
RBC transfusion requirements. In the univariate anal-
ysis the variables associated with primary anemia were
maximum creatinine level from 1 to 30 days after allo-
SCT (P 5 .001), low glomerular filtrate from 1 to 30
days after allo-SCT(P5 .008), positive cytomegalovirus
(CMV) antigenemia (P 5 .002), independently of
whether ganciclovir or foscarnet were used, and time
to platelet recovery (P5 .006) (Table 2). Twenty-eight
of the 41 (68.3%) patients with primary anemia had
a creatinine level during the first month after trans-
plantation higher than the median (1.3 mg/dL)
compared to only 4 of the 20 (20%) patients without
anemia (P 5 .0008). ABO incompatibility, condition-
ing regimen, CD341 cell dose, and source of stem cells
did not influence the incidence of primary anemia. In
the multivariate analysis 3 independent factors
predicted primary anemia: creatinine level after the
first month of transplantation (relative risk [RR]
6.04, CI 1.4-25.9, P5 .02), positive CMV antigenemia
(RR 11.2, CI 2.1-60.3, P5 .005), and delay in platelet
engraftment (RR 6.4, CI 1.4-28.9, P 5 .02).
Response to ESP
Thirty-five of the 41 (85.3%) patients were treated
with ESP. The remaining 6 patients with primary
anemia did not receive ESP because of the appearance
of severe comorbidities just before starting it. The first
11 patients received epoietin a (Eprex, Janssen-Cilag,
or Epopen, Pensa) and the remaining 24 patients
received darbepoietin alpha (Aranesp, Amgen),
because of its more convenient weekly administration.
In 5 patients response was not evaluable because of
early death (n 5 2), discontinuation of follow-up
because patients were referred to their original center
(n5 2), and early relapse (n5 1). Out of the 30 remain-
ing patients, 28 (93%) achieved a major and 1 (3.3%)
a minor response, this last case attaining an Hb level
superior to 10 g/dL without RBC transfusion. ESP
treatment was associated with a rapid rise in Hb
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Comparison of Characteristics of Patients without
Anemia and Patients with Primary Anemia
30 Days after Allogeneic Transplantation
No Anemia
(n 5 20)
Primary Anemia
(n 5 41) P
Age (years), median (range) 41.5 (20-61) 40 (19-61) .3
Sex (M/F), n (%) 12/8 (60/40) 26/15 (63.4/36.6) 1.0
ABO compatibility, n (%)
Compatible 11 (55) 18 (43.9) .5*
Minor incompatibility 6 (30) 14 (34.1) .7†
Major incompatibility 3 (15) 9 (22)
Maximum creatinine 1-30 days post-allo-SCT (mg/dL), median (range) 1.1 (0.9-2.2) 1.6 (0.8-3.7) .001
Glomerular filtrate 1-30 days post-allo-SCT (mL/min/) 80 (46-129) 60 (24-117) .008
Stage of disease, n (%)
Early 6 (30) 23 (56.1) .06
Advanced 14 (70) 18 (43.9)
Preparative regimen, n (%)
Myeloablative 13 (65) 29 (70.7) .7‡
TBI 11 24 .5§
No TBI 2 5
RIC 7 (35) 12 (29.3)
TBI - 2
No TBI 7 10
CD341 cell dose (106/kg body weight), median (range) 4.5 (1.1-10) 4.21 (0.9-16.45) .8
Stem cells, n (%)
PB 15 (75) 35 (85.4) .4
BM 5 (25) 6 (14.6)
Donor, n (%)
HLA-identical sibling 15 (75) 26 (63.4) .4¶
Unrelated 5 (25) 15 (36.6) 1.0t
Match 4 (20) 11 (26.8)
Mismatch 1 (5) 4 (9.8)
Acute II-IV GVHD, n (%) 2 (10) 13 (31.7) .1
CMV1Ag before day 1 90, n (%) 3 (15) 24 (58.5) .002
Median day (range) to reach ANC .0.5  109/L 16 (11-24) 18 (0-33) .2
Median day (range) to reach platelet count
. 20  109/L 12.5 (0-35) 18 (0-286) .01
. 50  109/L 17 (12-41) 25 (0-322) .006
M indicates male; F, female; TBI, total body irradiation; RIC, reduced-intensity conditioning; PB, peripheral blood; BM, bone marrow; ANC,
absolute neutrophil count; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
*ABO compatibility versus ABO incompatibility.
†ABO compatibility 1 minor ABO incompatibility versus major ABO incompatibility.
‡Myeloablative regimen versus RIC.
§Conditioning with TBI versus conditioning without TBI.
¶HLA-identical sibling versus UD.
tHLA-identical sibling and match unrelated donor versus mismatch donor.concentration, with Hb values being of 8.8 (range: 6.6-
10.1) g/dL before ESP treatment and of 11.6 (range:
8.9-14.5) g/dL after 1 month of drug administration
(P 5 6  10210) (Figure 1A), and with a rise in the
reticulocyte count, from 85 (range: 19.5-209.4)
109/L to 138.4 (range: 34.1-494)  109/L
(P 5 .008). The proportion of patients requiring
RBC transfusion before and after 1month of treatment
was 60% and 26.6%, respectively (P 5 .02)
(Figure 1B). Full-dose treatment (epoietin a 10,000
IU 3 times per week; darbepoietin 150 mg per week)
was discontinued after a median time of 42 (range:
18-230) days without further need of RBC transfusion.
After this period ESP dosage was tapered to maintain
an Hb level superior to 11 g/dL, so the median timeduration of the complete treatment was 240 (26-981)
days. A delayed response was observed in 2 patients;
in both of them iron deficiencywas detected and a rapid
Hb response was observed after oral iron administra-
tion. Only these 2 patients received supplements of
iron during ESP treatment.Of the whole group treated
with ESP, only 1 (3.3%) case did not respond after 3
months of treatment. A possible explanation of the
lack of response in this particular case is that a relapse
of the hematologic disease was observed shortly there-
after (Table 3). One patient presented with a deep vein
thrombosis in the left leg while receiving ESP treat-
ment concurring with an Hb level of 9.5 g/dL. Antico-
agulant treatment with low molecular weight heparin
was started with total resolution of the thrombosis.
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The median ferritin level before and after ESP
administration was 1628 (range: 168-5208) ng/mL
and 805 (range: 14-7443) ng/mL, respectively (P\.04)
(Figure 2). The proportion of patients with a ferritin
value superior to 1000 ng/mL before starting ESP
was 78% compared to 50% at the end of the treatment
(P5 .16).
Figure 1. (A) Hb response to ESP treatment; (B) RBC transfusion
requirements.
Table 3. Characteristics and Response to ESP Treatment
Time post allo-SCT to initiate ESP
treatment, median (range) days 83 (40-257)
Pre ESP treatment RBC transfusion, n (%)
No 12 (40%)
Yes 18 (60%)
Type of ESP, n (%)
erythropoietin a 11 (31%)
darbepoietin a 24 (69%)
Response to ESP treatment, n (%) 29/30 (97%)
Major 28
Minor 1
No evaluable, n (%) 5/35 (14.3%)
ESP treatment duration, median (range) days 240 (26-981)
Full dose 42 (18-230)
Maintenance 201 (23-952)
Iron supplement, n (%) 2/30 (6.7%)
ESP indicates erythropoiesis stimulating proteins; RBC, red blood
cells.DISCUSSION
Anemia associated with impaired Epo secretion
after allo-SCT is likely to be more frequent than
usually recognized. In our study, half of the patients
submitted to allo-SCT developed persistent anemia 1
month after transplantation, not associated to hemor-
rhage, graft failure, hemolysis, leukemic relapse, or
severe infection. All these patients had inadequately
low serum Epo levels, a well-known phenomenon after
allo-SCT that has been linked to cytokines release and
to the use of CsA [6,15,27-31].
IL-1 and TNF-a levels have been shown to be
increased after allogeneic transplantation, as a result
of acute or chronic inflammatory states, especially in
relation to GVHD [27]. These cytokines suppress
the marrow proliferative response by inhibiting Epo
production and by blocking its action on erythroid
precursor cells [28,29]. This mechanism would explain
the association between CMV infection and primary
anemia as found in this study. CMV infection induces
the release of macrophage and T cell-derived cyto-
kines that have been shown to inhibit the growth of
erythroid progenitors in vitro [30,31]. Moreover, it
has been also demonstrated that CMV infection causes
defective Epo production [6].
Regarding the association of CsA and impaired
Epo secretion, Vannucchi et al. [15] in 1991 found in
a mouse model that serum Epo levels were constantly
low in those CsA treated, a finding later corroborated
in humans [6]. Although the inhibitory effect of CsA
on Epo secretion was found to be independent from
the drug dose and creatinine level [6,15], a subclinical
kidney toxicity produced by CsA has been considered
the cause of the impaired Epo production [15]. Allo-
SCT may produce long-term renal dysfunction [32],
renal damage occurring within the first 3 weeks after
transplantation in most cases [32]. We selected this
period of time for identifying renal dysfunction as
Figure 2. Decrease of ferritin level.
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secretion and subsequent anemia. We found that renal
damage during the first month after allo-SCT is an im-
portant factor for further developing persistent ane-
mia, which is consistent with the notion that renal
disease is almost always accompanied by a profound
failure of the normal Epo response. Thus, 91.3% of
patients with creatinine higher than the median (1.3
mg/dL) developed anemia compared with 56.8% of
patients with normal creatinine level (P 5 .0005).
It would appear that renal insufficiency worsens the
already impaired Epo secretion because of CsA,
impeding in these patients to mount an adequate
erythropoietic response to anemia.
A number of different factors such as nephrotoxic
antibiotics, anti-inflammatory and antihypertensive
drugs, severe infections, and chemoradiotherapy may
contribute to the occurrence of renal toxicity after
allo-SCT, but CsA is a constant factor for this compli-
cation. In fact, the major limiting factors in the use of
CsA are the acute and long-term toxic effects over the
kidney [33,34]. In the short term, CsA induces a revers-
ible reduction in renal blood flow and glomerular fil-
tration rate [35]. In the long term, CsA treatment
leads to irreversible renal failure characterized by
extensive tubulointerstitial fibrosis [36]. The long-
term effects of CsA toxicity can be attributed to
sustained restriction of renal blood supply related to
a decreased nitric oxide production in renal arterioles
[37]. Notably, ESP reduces the consequences of oxida-
tive stress and promotes proangiogenic actions. Recent
reports, in which ESP were used to ameliorate renal
failure, are encouraging [38-41].Whether ESP admin-
istration for correcting anemia after allo-SCTwill also
be associated with improvement in renal function re-
quires specific investigations.
Although the inappropriate Epo secretion in
anemic patients after allo-SCT supports the use of
ESP in these patients, controlled trials have shown
little clinical benefit, including little reduction in
transfusion requirements and poor cost-effective ratios
[16-18,20]. Several reasons may explain these discour-
aging results. First, in most of these trials ESP was
administered in the early postransplantation period,
when in fact, there is high serum level of endogenous
Epo [8]. Second, patients were treated independently
of whether they were anemic or not, and regardless
of whether the anemia was because of impaired Epo
secretion or to other causes [21]. Third, the ESP
dose administered was very high, making it difficult
to justify their use on economic grounds. Amore ratio-
nal use of ESP after allo-SCT is mandatory, especially
considering that they can be associated to serious un-
expected events such as thromboembolic episodes.
Not surprisingly, EORTC guidelines state that for
allo-SCT patients ESP are only recommended on an
individual basis [42,43]. For ESP treatment, weselected patients with persistent anemia beyond the
first month of the transplantation, with inadequate
serum Epo level, and without other etiology for the
anemia. Only a small cohort of patients from the liter-
ature has received a very similar tailored ESP adminis-
tration [19]. Results from this series and those from
Baron et al. [19] show that primary anemia after allo-
SCT is exquisitely sensitive to ESP, with transfusion
independence and complete correction of Hb being
achieved in more than 95% of the patients. Our study
confirms that the majority of patients requires only
a short course of treatment to respond and that ESP
can be discontinued in the majority of responders
without requiring retreatment with ESP for recurrent
anemia [19,21]. Of note, response to treatment was
observed in all patients regardless of whether they
had received a myeloablative or RIC regimen. This is
in contrast to the finding of Baron et al. [44] that
suggested that RIC transplantations are not associated
with impaired Epo production.
Ironoverload after allo-SCT is frequently observed
in heavily transfused patients [2,45-48], and is associ-
ated with a higher probability of transplantation-
related mortality, mainly because of more frequent
organ toxicity and severe infections [2,3,49-52]. A
safe and simple measurement of ferritin level provides
an approximation of the total body iron content
[50,53]. Phlebotomy removes the excess of iron accu-
mulated but it is associated with anemia [50]. In
contrast, ESP administrationmight decrease iron over-
load by both avoiding repeated transfusions and by
utilization of deposits of iron [19,53-55]. Indeed, we
have observed that after ESP administration ferritin
levels significantly decreased. A similar finding has
been observed in healthy donors and in renal end-stage
patients treated with ESP [54-56].
In conclusion, anemia associated with impaired
Epo secretion after allo-SCT is more frequent than
recognized and is mainly observed in patients with
renal dysfunction during the first month after trans-
plantation. Although the etiology of primary anemia
after allo-SCT is multifactorial, and in addition to
low Epo levels, poor graft function, GVHD, and viral
infections may all contribute to reduce hemopoiesis,
it is exquisitely sensitive to ESP, with transfusion inde-
pendence and complete correction of Hb being
achieved in more than 95% of the patients. An addi-
tional benefit of ESP administration in these patients
is that it might contribute to reduce the incidence of
iron overload by eliminating the need of transfusions
and by mobilizing iron deposits. These results must
be validated in larger numbers of patients.
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